<strong><em>Background</em></strong><span style="font-family:Verdana;"><strong>:</strong></span><span style="font-family:;" "="">...<strong><em>Background</em></strong><span style="font-family:Verdana;"><strong>:</strong></span><span style="font-family:;" "=""><span style="font-family:Verdana;"> Despite of different adverse events, streptokinase (SK) is widely used to treat patients presented with acute ST segment elevation myocardial infarction. </span><b><i><span style="font-family:Verdana;">Objective</span></i><span style="font-family:Verdana;">:</span></b><span style="font-family:Verdana;"> The purpose of the present study was to observe different adverse events in patients of acute ST segment elevation myocardial infarction receiving SK infusion. </span><b><i><span style="font-family:Verdana;">Methodology</span></i><span style="font-family:Verdana;">:</span></b><span style="font-family:Verdana;"> This cross-sectional type of analytic observational study was carried out in the inpatient department of Cardiology at National Institute of Cardiovascular Diseases, Dhaka, Bangladesh from December 23</span><sup><span style="font-size:12px;font-family:Verdana;">rd</span></sup></span><span style="font-family:Verdana;"> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">2019 to February 22</span><sup><span style="font-size:12px;font-family:Verdana;">nd</span></sup><span style="font-family:Verdana;"> 2020 for a period of two (2) months. All patients diagnosed as acute ST segment elevation myocardial infarction receiving SK were included in the present study. Adverse events were documented through completing a questionnaire by reviewing the records in the medical file as well as interviewing with the patients. </span><b><i><span style="font-family:Verdana;">Result</span></i><span style="font-family:Verdana;">:</span></b><span style="font-family:Verdana;"> In this study, 43 (26.2%) patients developed different types of adverse events and 121 (73.8%) had no complications following SK infusion. The most common adverse event was hypotension </span><i><span style="font-family:Verdana;">i.e.</span></i><span style="font-family:Verdana;"> 26 (60.4%) and other adverse events were bleeding 8 (4.8%) and allergic reaction 7 (4.2%). Statistically significant higher rate of adverse events occurred in diabetic, hypertensive and dyslipidemia group which was 26 (56.5%) Vs. 17 (14.4%), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.000, 37 (36.6%) Vs. 06 (09.5%), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.000 and 18 (54.5%) Vs. 25 (19.1%), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.000 respectively. The independent factors for the development of adverse events were smoking {OR: 5.1</span></span><span style="font-family:Verdana;"> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">with 95% CI (1.7 to 15.1), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.003}, diabetes {OR: 14.9 with 95% CI (5.0 to 44.8), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.000}, hypertension {OR: 5.1with 95% CI (1.7 to 15.1), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.003} and dyslipidemia {OR: 4.6 with 95% CI (1.5 to 13.7), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.007}. </span><b><i><span style="font-family:Verdana;">Conclusion</span></i><span style="font-family:Verdana;">:</span></b><span style="font-family:Verdana;"> Streptokinase infusion was associated with different adverse events. Among them the commonest one was hypotension and other less common events were minor bleeding and minor allergic reaction. The adverse events were more frequently documented in patients who were smoker, diabetic, hypertensive and dyslipidemic.</span></span>展开更多
文摘<strong><em>Background</em></strong><span style="font-family:Verdana;"><strong>:</strong></span><span style="font-family:;" "=""><span style="font-family:Verdana;"> Despite of different adverse events, streptokinase (SK) is widely used to treat patients presented with acute ST segment elevation myocardial infarction. </span><b><i><span style="font-family:Verdana;">Objective</span></i><span style="font-family:Verdana;">:</span></b><span style="font-family:Verdana;"> The purpose of the present study was to observe different adverse events in patients of acute ST segment elevation myocardial infarction receiving SK infusion. </span><b><i><span style="font-family:Verdana;">Methodology</span></i><span style="font-family:Verdana;">:</span></b><span style="font-family:Verdana;"> This cross-sectional type of analytic observational study was carried out in the inpatient department of Cardiology at National Institute of Cardiovascular Diseases, Dhaka, Bangladesh from December 23</span><sup><span style="font-size:12px;font-family:Verdana;">rd</span></sup></span><span style="font-family:Verdana;"> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">2019 to February 22</span><sup><span style="font-size:12px;font-family:Verdana;">nd</span></sup><span style="font-family:Verdana;"> 2020 for a period of two (2) months. All patients diagnosed as acute ST segment elevation myocardial infarction receiving SK were included in the present study. Adverse events were documented through completing a questionnaire by reviewing the records in the medical file as well as interviewing with the patients. </span><b><i><span style="font-family:Verdana;">Result</span></i><span style="font-family:Verdana;">:</span></b><span style="font-family:Verdana;"> In this study, 43 (26.2%) patients developed different types of adverse events and 121 (73.8%) had no complications following SK infusion. The most common adverse event was hypotension </span><i><span style="font-family:Verdana;">i.e.</span></i><span style="font-family:Verdana;"> 26 (60.4%) and other adverse events were bleeding 8 (4.8%) and allergic reaction 7 (4.2%). Statistically significant higher rate of adverse events occurred in diabetic, hypertensive and dyslipidemia group which was 26 (56.5%) Vs. 17 (14.4%), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.000, 37 (36.6%) Vs. 06 (09.5%), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.000 and 18 (54.5%) Vs. 25 (19.1%), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.000 respectively. The independent factors for the development of adverse events were smoking {OR: 5.1</span></span><span style="font-family:Verdana;"> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">with 95% CI (1.7 to 15.1), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.003}, diabetes {OR: 14.9 with 95% CI (5.0 to 44.8), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.000}, hypertension {OR: 5.1with 95% CI (1.7 to 15.1), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.003} and dyslipidemia {OR: 4.6 with 95% CI (1.5 to 13.7), </span><i><span style="font-family:Verdana;">p</span></i><span style="font-family:Verdana;"> = 0.007}. </span><b><i><span style="font-family:Verdana;">Conclusion</span></i><span style="font-family:Verdana;">:</span></b><span style="font-family:Verdana;"> Streptokinase infusion was associated with different adverse events. Among them the commonest one was hypotension and other less common events were minor bleeding and minor allergic reaction. The adverse events were more frequently documented in patients who were smoker, diabetic, hypertensive and dyslipidemic.</span></span>